Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.

2022-11-17 07:55:12

Emplicure AB Interim Report Q3 2022

THIRD QUARTER, JULY-SEPTEMBER 2022

Net sales amounted to MSEK 0.0 (0.0)
Operating loss (EBIT) amounted to MSEK -4.5 (-4.0)
Net loss amounted to MSEK -4.5 (-4.0)
Net cash flow amounted to MSEK -7.4 (+20.1)
EPS before and after dilution amounted to SEK -0.17 (-0.20)

JANUARY-SEPTEMBER 2022

Net sales amounted to MSEK 0.0 (0.1)
Operating loss (EBIT) amounted to MSEK -20.5 (-11.5)
Net loss amounted to MSEK -20.5 (-13.3)
Net cash flow amounted to MSEK -9.1 (+23.4)
EPS before and after dilution amounted to SEK -0.90 (-1.00)

For additional information, please contact

Håkan Engqvist

CEO
Phone: +46 702 569 500
Email: [email protected]

Erik Magnusson

CFO
Phone: +46 708 565 245
Email: [email protected]

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

Senaste nytt

Emplicure AB Interim Report Q3 2022

Nerladdningsbara filer

Emplicure AB Bokslutskommuniké 2022

Emplicure AB Year-end report 2022

Emplicure AB Kvartalsrapport Q3 2022